Bradley Monk, MD
Enriched profileMedical Director, Late-Phase Clinical Research · Florida Cancer Specialists & Research Institute
Bradley Monk is Medical Director, Late-Phase Clinical Research at Florida Cancer Specialists & Research Institute. OpenAlex indexes 1,001 publications with 45,442 citations (h-index 94); ClinicalTrials.gov lists 18 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Gynecologic Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Bradley J. Monk, MD, is Medical Director, Late-Phase Clinical Research at Florida Cancer Specialists & Research Institute (West Palm Beach, Good Samaritan/Flagler). The public record shows 1,001 publications with 45,442 citations (h-index 94), centered on Ovarian cancer diagnosis and treatment, Endometrial and Cervical Cancer Treatments, PARP inhibition in cancer therapy. It also documents an investigator role on 18 registered clinical trials, industry payments reported by 58 companies.
- Most recent indexed publication: 2026 · JCO precision oncology
- Top research focus: Ovarian cancer diagnosis and treatment
- 18 registered trials on ClinicalTrials.gov
- Open Payments reporting from 58 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 41 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 422.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 18 registered studies on ClinicalTrials.gov. The most recent:
- ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
Sponsor: OncoC4, Inc.
Industry payments
Updated 27 Aug 2026
58 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- GlaxoSmithKline, LLC.Program year202544 payments$77,418openpaymentsdata.cms.gov ↗
- Merck Sharp & Dohme LLCProgram year202564 payments$64,654openpaymentsdata.cms.gov ↗
- Takeda Pharmaceuticals U.S.A., Inc.Program year20255 payments$46,802openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Aromatase Inhibitor100%Letrozole100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden-High Ovarian Cancer.
JCO precision oncology
Clinical Trial2026 - Decoding the End Points of Poly (ADP-ribose) Polymerase Inhibitor Trials in Ovarian Cancer.
Journal of clinical oncology
Letter2025 - Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation.
Journal of clinical oncology
Clinical Trial2025 - Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201.
Journal of clinical oncology
Clinical Trial2025 - Pembrolizumab plus chemotherapy with or without bevacizumab in East Asian participants with persistent, recurrent, or metastatic cervical cancer: results from KEYNOTE-826 final analysis.
Journal of gynecologic oncology
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)- 01
- 02Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer2,386 citations2011
- 03
- 04Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer2,265 citations2019
- 05Improved Survival with Bevacizumab in Advanced Cervical Cancer1,502 citations2014
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/bradley-monk-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/bradley-j-monk-md-4879a7155
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- Other
videopodcast.researchtopractice.com/ovarian-cancer-bradley-j-monk-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →videopodcast.researchtopractice.com ↗ - Other
emjreviews.com/oncology/congress-review/esgo-2025-insights-an-interview-with-bradley-monk
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →emjreviews.com ↗ - Facebook
facebook.com/FloridaCancerSpecialists/posts/were-proud-to-share-that-dr-bradley-monk-fcs-board-certified-gynecologic-oncolog/1389543439838593
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →media.mycme.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →media.mycme.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →media.mycme.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗
- Fellowship
Gynecologic Oncology, MD Anderson Cancer Center, Houston
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →flcancer.com ↗ - Fellowship
Medical Genetics, National Institutes of Health, Bethesda
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →flcancer.com ↗ - Board-certified
Gynecologic Oncology (FACOG, FACS)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →flcancer.com ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →media.mycme.com ↗
- Cervical Cancer Sub-Committee Chair
NRG Oncology (11 years)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →media.mycme.com ↗ - Prior Chair
Cervical Cancer Committee, Gynecologic Cancer Intergroup
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →media.mycme.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →flcancer.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →flcancer.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →flcancer.com ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →media.mycme.com ↗
- Prior: Associate Professor
Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, UC Irvine Medical Center (1998-2010); Director of Research, Dept. of OB/GYN
2010verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →media.mycme.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →media.mycme.com ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →emjreviews.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Satish Shanbhag, MD, MPH
Florida Cancer Specialists & Research Institute
Ivor Percent, MD
Florida Cancer Specialists & Research Institute
Bradford Perez, MD
Florida Cancer Specialists & Research Institute
Scott Lunin, MD
Florida Cancer Specialists & Research Institute